無料プレビュー

Collegium Pharmaceutical, Inc. (COLL) · NASDAQ Global Select

プロフィール

Collegium Pharmaceutical develops, licenses, and commercializes a diversified portfolio of prescription medications for attention deficit hyperactivity disorder and moderate to severe pain in the United States. Its product portfolio includes Jornay PM (an evening-dosed ADHD stimulant), Belbuca (buprenorphine for severe pain), Xtampza ER (abuse-deterrent oxycodone), Nucynta Products (tapentadol formulations), and Symproic (opioid-induced constipation treatment). The company markets these products through dedicated field sales forces targeting pain specialists and ADHD prescribers, primarily sel

主要指標

株価: $22.01 (-0.47%)
時価総額: 7億ドル
PER（今期予想）: 3.0
PBR: 2.3
配当利回り: —
52週レンジ: $21.43 – $50.79
業種: Healthcare / Drug Manufacturers - Specialty & Generic
上場: NASDAQ Global Select
構成銘柄: —

比較会社: TAK Takeda Pharmaceutical Company Limited、TEVA Teva Pharmaceutical Industries Limited、HLN Haleon plc、ZTS Zoetis Inc.、VTRS Viatris Inc.、ITCI Intra-Cellular Therapies, Inc.、CTLT Catalent, Inc.、ELAN Elanco Animal Health Incorporated

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-05 · 更新: 2026-10-09